CA1072087A - Amides as ovulation inhibitors - Google Patents

Amides as ovulation inhibitors

Info

Publication number
CA1072087A
CA1072087A CA263,700A CA263700A CA1072087A CA 1072087 A CA1072087 A CA 1072087A CA 263700 A CA263700 A CA 263700A CA 1072087 A CA1072087 A CA 1072087A
Authority
CA
Canada
Prior art keywords
methoxy
ethyl
acetamide
chloroindol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA263,700A
Other languages
French (fr)
Inventor
Michael E. Flaugh
James A. Clemens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/720,311 external-priority patent/US4087444A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of CA1072087A publication Critical patent/CA1072087A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/26Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00Compounds containing nitroso groups bound to a carbon skeleton
    • C07C207/04Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE

The present invention relates to novel N-[2-(5-methoxy-6-haloindol-3-yl)ethyl]amides which are valuable, orally active, ovulation inhibitors.

Description

~z~

The present invention relates to novel N-~2-(5-methoxy-6-haloindol-3-yl)ethyl]amides which are valuable, orally active, ovulation inhibitors.
Melatonin (N-acetyl-5-methoxytryptamine) is a natural product isolated from the pineal glands of beef cattle. It is reported by Ying and Greep, Endocrinolog~l 92 (1), 333-5 (1973), that melatonin has an inhibitory e~fect on ovulation in cyclic rodents. This inhibitory efect is realized when melatonin is administered intracardially in relativèly large doses during the critical period of pro-estrus. However, when melatonin is administered orally, its inhibitory effect on ovulation is substantially diminished over that available by intracardial administration. It now has been discovered that a particular class of tryptamines, N-acyl-5-methoxy-6-halotryptamines, exhibit a high level of activity as ovulation inhibitor even when administered orally.
~he present invention provides novel compounds of the formula H
T~ R 3~ CH0 2 X ~ R
~ I
,, R2 .' in which R is hydrogen, Cl-C4 alkyl, phenyl, or phenyl substituted with halo, Cl-C4 alkyl or Cl-C4 alkoxy;

Rl is hydrogen or Cl-C4 alkyl;

X-3964~ -2-_ . .. . _ . . . ... . ... _ .. .
, . .. . . . . .. . . .. . .. . .

~L~7;~7 R2 is hydrogen or R3, and R3 is haloacetyl, Cl-C5 : : .
,: -alkanoyl, benzoyl, or benzoyl substituted withhalo or methyl; and X is halogen. :
The present invention also provides a process for .~ :
preparing novel 5-methoxy-6-halotryptamine compounds of formula I wherein R, Rl, R2, R3 and X are as defined above, which comprises reacting a 5-methoxy-6-halotryptamine com-pound of the formula ~ o-CH -CH -NH II

., I .
H ~ :
; wherein R and X are as defined above, with an active derivative of a carboxylic acid of the formula : O
-C-OH III

:: wherein Rl is as defined above; and if desired reacting the compound so obtained wherein R2 is hydrogen with an acylating agent of the formula R3-Cl IIIa ~;
wherein R3 is as defined above, in the presence of a strong base.
Compounds of formula I are orally active as inhibitors of ovulation in mammals.
Preferred compounds of formula I are those in which R2 is hydrogen.

~L072~ 7 Another preferred class of compounds of formula I
are those in which R~ is haloacetyl, Cl-C5 alkanoyl, benzoyl, or benzoyl substituted with halo or methyl.
In the definition of the compounds of this in- ~ -vention, the term "Cl-C4 alkyl" is employed. By this term ~ -is meant any of the following groups: methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, and t-butyl.
~he term "Cl-C4 alkoxy" also is employed herein ~ ;~
and includes methoxy, ethoxy, n-propoxy, isopropoxy, n butoxy, isobutoxy, sec-butoxy, and t-butoxy.
The terms "halo" and "halogen" where used herein include chlorot bromo, iodo, and fluoro, and, preferably, chloro.
When, in the above definition, the term R repre-sents a substituted phenyl group, examples of such a group include 4-chlorophenyl, 2-fluorophenyl, 3-iodophenyl, 4-bromophenyl, 3,4-dibromophenyl, 4-methylphenyl, 2~ethylphenyl, 3-n-propylphenyl, 4-isopropylphenyl, 4-n-butylphenyl, 3-2Q t-butylphenyl, 4-sec-butylphenyl, 3,4-dimethylphenyl, 4-methoxyphenyl, 3-ethoxyphenyl, 2-n-propylphenyl, 4-iso-propoxyphenyl, 3-isobutoxyphenyl, 4-t-bu~oxyphenyl or 3-ethoxy~4-methoxyphenyl.
The term "haloacetyl" as used herein in definition of the group R2 refers to chloroacetyl, bromoacetyl, fluoro-acetyl, and iodoacetyl~
The term "Cl-C5 alkanoyl" as used herein with reference to the group R2 includes formyl, acetyl, propionyl, butyryl, a-methylpropionyl, valeryl, a-methylbutyryl, 1~7Z0~37 .
~-methylbutyryl, and pivaloyl. Preferred Cl-C5 alkanoyl~ ~
groups are acetyl and pivaloyl, and, most preferably,;:
acetyl.
The term "benzoyl substituted with halo" used in :~ :
definition of the group R2 defines mono- and dihalobenzoyl groupsO Specific monohalobenzoyl groups are chlorobenzoyl, bromoben~oyl, fluorobenzoyl, and iodobenæoyl. Preferably, . the monohalobenzoyl group is a 4-halobenzoyl, and the ;:
`: preferred halo substituent is chloro.
The dihalobenzoyl groups defined by R2 generally are those in which both of the halo substituents are the ~:
same, and, preferably, are those in which the halo substituents are located in the 2- and 4-positions. Typical dihalo-benzoyl groups include 2,4-dichlorobenzoyl, 2,4-dibromo-; benzoyl, 2,4-difluorobenzoyl, and 2,4-diiodobenzoyl. The preferred group is 2,4-dichlorobenzoyl.
The term "benzoyl substituted with methyl" con-templates "methylbenzoyl", "dimethylbenzoyl", and "tri-methylbenzoyl'l. Preferred groups include 2-methylbenzoyl,
2,6-dimethylbenzoyl, or 2,4,6-trimethylbenzoyl.
Examples of the compounds of formula I include the following:
N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]acetamide;
N-~2-(5-rnethoxy-6-fluoroindol-3-yl)ethyl]acetamide;
~ N-[2-(5-methoxy-6-brornoindol-3-yl)ethyl]formamide;. ~-; N-[2-(5-methoxy-6-iodoindol-3-yl)ethyl]propi-onamide;
N-[2-(5-methoxy 6-chloroindol-3-yl)ethyl]-n-butyrarnide;

~72~\87 : `

N [2-(2-methyl-5-methoxy-6-bromo.indol-3-yl)ethyl]-acetamide;
N-[2-(2-ethyl-5-methoxy 6-chloroindol 3-yl)ethyl~
: acetamide;
.,: N-[2-(2-n-propyl-5-methoxy 6-chloroindol-3-yl)-ethyl]formamide; . .
``~ N-[2-(2-n-butyl-5 methoxy-6-chloroindol-3-yl)-~, e~hyl]formamide;
N-[2-~2 ethyl-5-methoxy-6-iodoindol 3-yl)ethyl]-. 10 propionamide;
: N-[2-(2-isopropyl-5-methoxy-6-fluoroindol-3-yl)- ~1.. :
." ~ ~
:l ethyl]-a-methylpropionamide; .~
1 N-[2-(2-phenyl-5-methoxy-6-chloroindol-3-yl)ethyl]- :.;
¦ formamide; ;.
:~l N [2-(2-phenyl-5-methoxy-6-bromoindol-3-yl)ethyl]-acetamide;
N-[2-(2-phenyl-5-methoxy-6-iodoindol-3-yl)ethyl]- '~
propionamide; ~ .
N-12-((2-(4-chlorophenyl)-5-methoxy-6-chloroindol -20 3-yl)~ethyl]formamide; ~;:
` N-[2-((2-(3-~luorophenyl)-5-methoxy-6-bromoindol-
3-yl))ethyl]acetamide; -N-[2-((2-(2-fluorophenyl)-5-methoxy-6 chloroindo].-3-yl))ethyl]propionamide;
N-[2-((2-~4-methylphenyl)-5-methoxy-6-bromoindol-3-yl))ethyl]formamide; ~
N-[2-((2-(3-ethylphenyl)-5-methoxy-6-fluoroindol- :
3-yl))ethyl]butyramide;
; N-[2-((2-(4-n-propylphenyl)-5-methoxy-6-chloro-indol-3-yl))ethyl]formamide;
: X-3964A -6-' ~' ~L~7Z~87 N-[2-((2-(3-isopropylphenyl)-5-methoxy-6-fluoro-indol-3-yl))ethyl3acetamide;
N-[2-((2-(4 methoxyphenyl)-5-methoxy-6 chloroindol- :
3-yl))ethyl]propionamide;
N-[2-((2-(3-ethoxyphenyl)-5-methoxy-6-bromoindol- :
3-yl))ethyl]acetamide;
N-E2-((2-(3-n-propoxyphenyl)-5-methoxy-6-fluor indol-3-yl))ethyl]acetamide;
N-[2-((2-(4-t-butoxyphenyl)-5-methoxy-6-chloro-indol-3-yl))ethyl]formamide;

.. . .
N-[2-((2-(3-n-butoxyphenyl)-5-methoxy-6-chloro-; indol-3-yl))ethyl]acetamide;

N-[2 (1-acetyl-5-methoxy-6-chloroindol-3-yl)-ethyl]acetamide;

: N-[2~ propionyl-5-methoxy-6-fluoroindol-3-yl)ethyl]acetamide;

N-[2-(1-pivaloyl-5-methoxy-6-bromoindol-3-yl)-; ethyl]formamide;

N-[2-(1-chloroacetyl-5-methoxy-6-iodoindol-3- :

yl)ethyl]propionamide;

N-[2-(1-bromoacetyl-5-methoxy-6-chloroindol-3-yl)ethyl]-n-butyramide: :

N-[2-(1-valeryl-2-methyl-5-methoxy-6-bromoindol-3-yl)ethyl]acetamide;

N-[2-(1-butyryl-2-ethyl 5-methoxy-6-chloroindol- i 3-yl)ethyl]acetamide;

N-[2-~1-benzoyl-2-n-propyl-5 methoxy-6-chloroindol-3-yl)ethyl]formamide;

~ N-[[2-[1~(4-chlorobenzoyl)-2-n-butyl-5-methoxy-6-: 30 chloroindol-3-yl]ethyl]]formamide;

Z~8'7 . ~
N-[ L2- [1- (4-bromobenzoyl)-2-ethyl-5~methoxy-6- -iodoindol-3-yl]ethyl]]propionamide; ~: ~
N-~[2-[1-(2,4-dichlorobenzoyl)-2-isopropyl-5- . ~ -; methoxy-6-fluoroindol-3-yl]ethyl]]-a-m~thylpropionamide; ~ .
N-[[2-[1-(2,4-di1uorobenzoyl)-2-phenyl-5-methoxy-6-chloroindol-3-yllethyl]]formamide; : :
N-[[2-[1 (4-iodobenæoyl)-2-phenyl-5-methoxy-6-bromoindol-3-yl]ethyl]]acetamide; ~ ~-N-[[2-[1-(2-methylbenzoyl)-2-phenyl-S-methoxy-6- -~
iodoindol-3-yl]ethyl]]propionamide;
N-[[2-[1-(2,6-dimethylbenzoyl)-2-(4-chlorophenyl)- .~ .
5-methoxy-6-chloroindol-3-yl]ethyl]]formamide;

i N-[[2-[1-(2,4,6-trimethylbenzoyl)-2-(3-fluoro phenyl)-5-methoxy-6-bromoindol-3-yl]ethyl]]acetamide;
N-[2-(1-pivaloyl-5~methoxy-6-chloroindol-3-yl)-ethyl]acetamide; .
;
N-[2-(1-chloroacetyl-5-methoxy-6-chloroindol-3-yl)ethyl]acetamide; -N-[[2 ~1-(4-chlorobenzoyl)-5-methoxy-6-chloro-~ :
. .
indol-3-yl]ethyl~]acetamid~;
~ -[[2-[1-(2,4-dichlorobenzoyl~-5-methoxy-6-chloroindol-3-yl]ethyl]]acetamide;
N-[[2-[1-(2-methylbenzoyl)-S-methoxy-6-chloro-indol-3-yl]ethyl~l-acetamide; ;, N-[[2-[1-(2,6-dimethylbenzoyl)-5-methoxy-6-~: chloroindol-3-yl]ethyl]]acetamide;
N-[~2-[1-(2,4,6-trimethylbenzoyl)-5-methoxy-6-chloroindol-3-yl~ethyl]]acetamide;
.:. and the like.
..

, :.
'', ~'` ' .

~7~87 The compounds of formula I are prepared by acylating a substituted tryptamine of the formula R

H
in which X and R are as aforedescribed. The acylation is accomplished by employment of conventional procedures. For ` example, the substituted tryptamine can be reacted with an - 10 activated form of a carboxylic acid of the formula O ~
" III

in which Rl is as defined hereinabove. Suitable such ac-tivated forms include, Eor example, the anhydride or mixed anhydride of the carboxylic acid. Acylation also can be carried out by reacting the carboxylic acid in the form of ; its acid halide with the tryptamine in the presence of a ~-hydrogen halide acceptor. Hydrogen halide acceptors which ; can be used include a tertiary amine, such as pyridine, or triethylamine; alkylene oxides, such as propylene oxide;
urea and substituted ureas, such as N-methylurea; and inorganic bases, such as sodium bicarbonate, potassium bicarbonate, sodium carbonate, or sodium bisulfite.
The substituted tryptamines used as starting ma-terials in the aforedescribed acylation are prepared by a variety of known procedures. A preparation of 5-methoxy-6-halotryptamines is illustrated by the following generalized reaction scheme:

~ i CH O ~ \ CHGH30~ ~ \ /C~13 `-NH ~ O ~ ----~------- 3 (IV) (V) pyridine HCI
~ /
HO\ ~ \ /CH HO~ ~ \ /CH3 T O ~ HONO ~ ~
X/~ ~ \NO ~ HOAc~b~ /o :

~¦~ 3 M S
h K2C3H30~T~ \ ~/CH3 ::

X ~o/ NO2 DMMe IX ~,,/ NOæ
(VIII) (IX) (MeO)2CHNMe2 ~ / DMF

CHDO~ HCHoO~ ~ \ ~ I = CHN(CH ) X~ ~ ~ / \N / Ra Ni / ~2 (XI) H (X) .
CH O
Et2NH ~' : HOAc : H O
~ /Z
: NaCN
DMF
MeOH
: H O ~
: Mel `:
~. / ` ! ~
~ ~ \ o-----o--C~ CN CHD ~ --C~I -C~l~-X ~ / \N / AIH3 ~ X~

3 0(XII ) H LHAFIH~ (XIII ) : .

! . : . . ~ : ' . . ~ ` " ' : ., ' . ~ ' ' ; ' ` ~L07~2~87 - :, As shown in the above generalized reaction scheme, the 5-methoxy-6-halotryptamines are prepared by first halo-genating 3-methoxy-4-aminotoluene (IV) to give 3-methoxy-4-halotoluene (V). The halogenated compound then is reacted with pyridine hydrochloride at an elevated temperature in the range of from about 180C. to about 240C. to provide a 2-halo-5-methylphenol (VI). The phenol is reacted with sodium nitrite in acid solution at a temperature from about ;
0C. to about 20C. to give an intermediate nitroso compound ~VII). Reaction of the nitroso compound with aqueous nitric acid at a temperature in the ranye of from about 30C. to about 60C. provides a 2-halo-4-nitro-5-methylphenol (VIII).
In those cases in which X is chloro, the 2-chlorophenol intermediate compound is commercially available and thus may itself be used as the initial starting material.
The halonitrophenol then is alkylated, for example, by refluxing it with dimethyl sulfate and potassium car-bonate in methanol or ethanol, or by heating it with methyl iodide and potassium carbonate in N,N-dimethylformamide, to provide 2~nitro-4-halo-5-mPthoxytoluene (IX). The nitro-toluene compound is reacted with N,N-dimethylformamide di-methylacetal in N,N-dimethylformamide at a temperature of from about 100C. to about 130C. to give an N,N-dimethyl-2-(2'-nitro-4'-halo-5'-methoxyphenyl)ethyleneamine intermediate (X), which, upon hydrogenation over Raney nickel, cyclizes to give a 5-methoxy-6-haloindole (XI).
The haloindole then is treated with diethylamine and formalin in aqueous acetic acid solution. The resulting mixture is added to aqueous base, and the total is extracted.

' -l~Z~t~7 The solvents are evaporated, and the recovered intermediate ;~
product is dissolved in a mixture of water, methanol and N,N-dimethylformamide and is reacted with sodium cyanide.
Methyl iodide then is added dropwise to the solution to give a 3-cyanomethyl-5-methoxy-6-haloindole (XII). The cyano compound is reduced with a metal hydride, for example, lithium aluminum hydride, to provide the desired 5-methoxy-6-halotryptamine (XIII).
Tryptamines having a substituent at the 2-position of the indole moiety are prepared by a modification of the aforedescribed sequence. Compound (X), prepared as described above, is treated with a compound of the formula O . .
R'-C-Y
in which Y is halo and R' is Cl-C4 alkyl, phenyl or sub-stituted phenyl as aforedescribed. This reaction is carried out in the presence of triethylamine or pyridine and at room temperature to produce the corresponding 2-acyl substituted ethyleneamine (XIV). The ethyleneamine then is treated with hydrochloric acid in aqueous dioxane at a temperature of about 100C. to produce the corresponding 2-nitro-4-halo-5-methoxybenzyl ketone (XV). The latter is ring-closed by treatment with hydrogen over Raney nickel at a temperature of about 25C. to about 40C. to the desired 2-substituted indole (XVI~. This sequence is illustrated by the following generalized reaction scheme:

X~3964A -12 . ~ ~

~ 7z~

o H3C0~ ~ \ /CH = CHN(CH~)2 R'-C-Y
R pyr i d ï ne (X) or triethylamine R' C = O
I HCI
H C0 ~ ~ CHN(CH ) H 0 t R dioxane ~N02 reflux 1 0 (XIV) Il H2 H C0 ~ \ ~CH -C-R' Raney 3 ~ ~ 2 _Nlckel___~
Benzene X ~ a ~ NO2 (~7) H~CO~

: X ~ ~ N R' (~VI) H

Compound (XVI) then is treated in the manner aforedescribed with reference to compound (XI) to produce the desired tryptamine. ~.
Alternatively, the indole, whether unsubstituted at the 2-position (compound XI) or substituted at the 2-position (compound XVI), can be treated by the following . generalized scheme to produce the desired tryptamine inter-mediate:
' . .

~:, ~;

7 - ~
: ~.
o .:
~ ~ DMF 3 ~

X~ ~ N20H X ~/ \N/ R
. .
H (XVII) H
(XI or XVI) NH40Ac H C0 ~ \ H CO~ CH=CHNO
3 t j~ --b--CH -CH -NH 3 X ~ R ~ LIAIH4 X ~/ \N/ \R ~ `

(XIX) H AIH3 ~XV~II) H ~ -As shown by the above generalized scheme, the indole is treated with phosphorus oxychloride and DMF to produce the corresponding 3-formyl indole (XVII). The latter is treated with nitromethane and ammonium acetate to obtain the corresponding 3-(2'-nitroethenyl)indole (XVIII), which then is reduced to the desired tryptamine (XIX)~
Compounds of formula I in which R2 is other than hydrogen are prepared from the N-unacylated compounds.
They are prepared by treating the latter with an appropriate acylating agent. Typically, the N-unacylated compound is reacted with at least an equimolar amount of an acyl halide of the formula R3Cl in which R3 represents any of the groups defined above. The reaction is carried out in the presence of a moderate molar excess (about 10%) of a strong base such as sodium hydride at room temperature in an inert solvent and for a time sufficient to accomplish conversion.

~, .

, `` :

~7;~37 The compounds of formula I exhibit an inhibitory effect on ovulation when administered orally. This inhibitory effect is markedly superior to the effect achieved by oral administration of melatonin. Thus, the compounds of formula I are especially useful as orally active inhibitors of o~ulation in birds and mammals. As a result, therefore, the compounds of formula I are useful in controlling the animal ; `~
population and as contraceptives in living beings. The compounds of formula I also are valuable for animal pest control. For example, the compounds of formula I can be formulated in combination with baits and/or attractants and placed in feeding stations accessible to undesirable rodents and other small animals including Canidae such as coyotes, foxes, wo~ves, jackals, and wild do~s; and birds, such as starlings, gul]s, redwing blackbirds, or pigeons, to greatly reduce the population thereof. By reason of the activity of the compounds of formula I, they can be used to reduce hazards to aviation by lessening the presence of birds and animals on runways and in the vicinity of air fields. The `~
compounds also can be used to reduce the population of undesirable birds and animals so as to aid in the prevention and the spread of disease, and to reduce the destruction of property in both rural and urban areas.
The compounds of formula I can be administered as such, or they can be compounded and formulated into phar-maceutical preparations in unit dosage form for oral or parenteral administration. In the compounding or formulation, organic or inorganic solids and/or liquids which are pharma-seutically acceptable carriers can be employed. Suitable _. . . .. , __ ..

~ 7;~q~87 such carriers will be well recognized by those of ordinary skill in the art. The compositions may take the form of tablets, powder granules, capsules, suspensions, or solution.
The compounds of formula I when administered in an effective amount, will produce the inhibition of pregnancy in birds and mammals. The usual daily dose is ~rom about 0.02 milligrams to about 20 milligrams per kilogram body weight of the recipient. The preferred daily dose is from about 1 milligram to about 8 milligrams per kilogram body weight of the recipient.
The following examples are provided to fuxther illustrate this invention. They are not intended to be limiting upon the scope thereof.
Example 1 N-[2-(5 ~5ethoxy-6-chloroindol-3-yl)ethyl]acetamide , A mixture of 142 g. `~1.10 mole) of 2-chloro-5-methylphenol in 300 ml. of acetic acid and 40 ml. of ; sulfuric acid was preparedO The mixture was stirred, and a solution of 70 g. of sodium nitrite in 200 ml. of water was added dropwise over a period of about 100 minutes. During the sodium nitrite addition the temperature of the mixture was maintained at 8-12C. with an ice-salt bath. After the addition was completed, the mixture was stirred for another 30 minutes and then was poured into a large volume of ice water. The crude 2-chloro-4-nitroso-5 methylphenol was collected by filtration and used without further purification.
The crude nitroso compound was added in portions to a stirred solution of 100 ml. of 70~ nitric acid and 300 ml. of water maintained at a temperature of about 40-50C.

~L~7ZC~g~7 ..
Heating and stirring were continued until the evolution of brown fumes ceased. The mixture was then poured into water, and the product was collected by filtration. The product was recrystalliæed from ethanol-water. After collecting the first crop, the mother liquor was concentrated and chilled to yield a second crop of product. Total yield was 155 g.
(83~) of 2-chloro-4-nitro-5-methylphenol, m.p. 142-4C.
A mixture of 25 g. ~0.133 mole) of the 2-chloro-4-nitro-5-methylphenol, 20 g. (0.145 mole) of potassium car-bonate, and 14 ml. (18.6 g.; 0.148 mole) of dimethyl sulfate in 500 ml. of absolute ethanol was refluxed for two hours.
An additional 19 g. of potassium carbonate and 5 ml. of dimethyl sulfate were added to the mixture, and refluxing was continued for two hours. After cooling, the mixture was poured into one liter of cold water and extracted with several portions of ether. The ether extracts were combined, mixed with methylene chloride, and washed with water. The extracts then were dried over sodium sulfate, and the soIvents were removed in vacuo. The residue was washed with petroleum ether and dried to yield 26.4 g. (94 percent) of 2-nitro-4-chloro-5-methoxytoluene.
A solution of 15.1 g. (0.075 mole) of the 2-nitro-
4-chloro-5-methoxytoluene, 10.7 g. (0.09 mole) of N,N-di-methylformamide-dimethylacetal, and 1.0 g. of triethylenedi-amine in 100 ml. of N,N-dimethylformamide was heated over-night at about 120C. in a distillation apparatus under a gentle nitrogen sweep to yield N,N-dimethyl-2-(2'-nitro-4'-chloro-5'-methoxyphenyl)ethyleneamine. The intermediate was not isolated. Instead, it was hydrogenated in situ over ~.~72~7 0.4 g. of Raney nickel at 15 psi during which time the temperature rose to 40-50C. The hydrogenated solu~ion was filtered, and the filtrate was poured into 500 ml. of ice water containing 10 ml. of acetic acid. The resulting mixture was extracted with several portions of methylene -chloride. The co~bined organic extracts were washed with sodium chloride solution and dried over sodium sulfate. The solvent was removed, and the crude product was sublimed at 4 mm. pressure and 130~C. The colorless sublimate was recrystallized from methanol-water to yield 6.1 g. (45 percent) of 5-methoxy-6~chloroindole, m.p. 126-28C~ ~
A solution of 14 ml. of 60 percent acetic acid and ! ~;
4.8 g. of diethylamine was prepared and cooled to about 5C.
To this solution were added 5.1 ml. of formalin. After stirring for ten minutes, the cold solution was added to a cold solution of 10 g. (55 mmole) of 5~methoxy-6-chloro- -indole in 20 ml. of absolute ethanol. The solution was allowed to warm to room temperature and was stirred for one hour. The solution then was poured into 200 ml. of cold lN
sodium hydroxide, and the mixture was extracted several ,~
times with ether. The combined ether extracts were washed with sodium chloride solution, dried over sodium sulate, and the solvent removed in vacuo.
The residue was ta]cen up in a solution of 200 ml.
of methanoll 10 ml. of N,N-dimethylformamide, 10 ml. of water and 13.3 g. (0.27 mole) of sodium cyanide. To this solution were added dropwise over a period of about one hour ~; 21 ml. (48 g., 0.34 mole) of methyl iodide. After the addi- ;
tion of methyl iodide was complete) the solution was stirred :' ` ~7;~87 for about one hour and then was poured into ice water. The aqueous mixture then was extracted with methylene chloride.
The extract was dried over sodium sulfate, and the solvent was removed in vacuo. The residue was recrystallized from an ether-pentane mixture to yield 6.1 g. (50 percent) of 3-cyanomethyl~5-methoxy-6-chloroindole, m.p. 133-137C.
A solution 7.6 g. (0.2 mole) of lithium aluminum hydride in 200 ml. of tetrahydrofuran was stirred under nitrogen while a solution o 5.2 ml. (9.8 g.~ 0.1 mole) of 100 percent sulfuric acid in 40 ml. of tetrahydrouran was added. A solution of 6.0 g. (27 mmoles) of 3~cyanomethyl-
5-methoxy-6-chloroindole in 40 ml. of tetrahydrofuran then was added over a 30-minute period. The reaction was allowed to proceed for another hour with stirring. The mixture then was poured into ice followed by 20 percent sodium hydroxide solution. The resulting mixture was extracted with several portions of chlorofo~m. The extracts were washed with sodium chloride solution, dried over sodium sulfate, and the solvent was removed in vacuo. The residue was boiled in ether, and a small amount of pentane was added. The mixture was cooled, and the crystalline product collected by fil-tration. Ater drying, 5.04 g. (83 percent) of 5-methoxy-
6-chlorotryptamine were obtained.
To a solution of 0.5 g. (2.23 ~oles) of the tryptamine in 5 ml. of pyridine was added 0.5 ml. of acetic anhydride. The mixture was allowed to stand overnight. The solvent was removed ln vacuo, and the residue was taken up in a mixture o chloroform and ethyl acetate. The solution was washed with sodium bicarbonate solution and dried over .. . . . .. .. . .. .

~ 72~8~ ~

sodium sulfate. The solvent was removed ln vacuo. Theresidue was boiled in benzene. After cooling the product was collected and the benzene treatment was repeated. The product then was dried to yield 0.52 g. (87 percent) of N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]acetamide, m.p.
149 d 5 150 C~
Example 2 N-[2-(5-Methoxy-6-chloroindol~3-yl)ethyl3propionamide A solution of 0.5 g. (2.23 mmole) of 5-methoxy- `
6-chlorotryptamine, prepared as described in Example 1, in 4 ml. of benzene and 1 ml. of pyridine was acylated with propionic anhydride following the procedure described in Example 1. N-[2-(5-Methoxy-6-chloroindol-3-yl)ethyl]propi-onamide, 0.56 g., m.p. 100-101C~, was obtained.
Example 3 ; N-[2-(5-Methoxy-6-chloroindol-3-yl)ethyl]butyramide A solution of 0O5 g. (2.23 mmole) of 5-methoxy-6-chlorotryptamine, prepared as described in Example 1, in 5 ml. of pyridine was acylated with butyryl chloride following the procedure described in Example 1. N-[2-(5-Methoxy-6-chloroindol-3-yl)ethyl]butyramide, 0.41 g. (62 percent), m.p. 98-98.5C., was obtained.
ExamPle 4 N-[2-(5-Methoxy-6-fluoroindol-3-yl)ethyl~acetamide To 68.5 grams (0.5 mole) of 2-methoxy-4-methyl-aniline in a 2 liter flask was added a solution of 136 ml.
of concentrated hydrochloric acid in 930 ml. of water. The solution was cooled and stirred at about -5~C., and a solu-tion of 42 grams (0.61 mole) of sodium nitrite in 110 ml. of .

.

~07Z01~7 water was slowly added. The mixture was maintained atabout -5C. for about 2~ minutes after which 75 ml. (0.60 mole) of 65 percent aqueous hexafluorophosphoric acid were rapidly added. ~he resulting mixture was stirred and maintained cold for about 30 minutes, and the resulting product then was collected by filtration. The product was washed with 400 ml. of cold water followed by a solution of 120 ml. of methanol and 460 ml. of ether. The resulting diazonium hexafluorophosphate salt was collected on a filter and dried ln vacuo overnightO The resulting dried salt ; weighed 1S5 grams (96 percent).
A 1 liter flask containing 500 ml. of mineral oil was fitted with a reflux condenser, a magnetic stirrer, a thermometer, and a connecting tube leading to a 300 ml.
Erlenmeyer flask. To the Erlenmeyer flask was added the entire quantity of the diazonium salt. The oil was heated to 165C. by means of an oil bath. The diazonium salt then was added in portions over a 45 minute period. There was a slightly exothermic reaction. Upon complet.ion of the re-20 action, the flask was rapidly cooled and 400 ml. of 10 percent aqueous sodium carbonate solution were ¢autiously added. The mixture was subjected to steam distillation.
The resulting oily layer was collected. The aqueous layer was extracted with 350 ml. portions of methylene chloride. ;
The methylene chloride extracts were added to the oil, and the entire mixture was dried over sodium sulfate. The solvent was removed in vacuo, and the product was distilled to obtain 34.2 grams of 3-methoxy-4-fluorotoluene, b.p. 30 mm 93_95C.

. . . ~ .:. . : : ,, , 72~137 To a 500 ml. ~lask were added 200 grams of pyridine hydrochloride. The flask was fitted with a magnetic stirrer, a reflux condenser, and a nitrogen bubbler. The pyridine salt was heated to about 180C. to remove any moisture. The salt then was allowed to cool somewhat, and 34 grams (0O243 mole) of the fluorotoluene compound were added. The mixture ; was heated to 220C. and maintained there for about three hours. The mixture then was cooled, and a large volume of water was added. The reaction mixture then was extracted with several portions of methylene chloride. The methylene chloride extracts were combined, and the solvent was removed n vacuo to obtain a pale yellow product which by nmr analysis indicated the presence of about 5 percent of starting material. The product then was taken up in an excess of lM sodium hydroxide. The solution was extracted with methylene chloride, and the aqueous layer then was acidified with hydrochloric acid. The acidified portion was extracted with methylene chloride. Evaporation of the methylene chloride extract and distillation of the residue gave 26.6 yrams of 2-fluoro-5-methylphenol, b.p.30 86-93C.
A solution of 26.6 grams (0.21 mole) of the fluorophenol in 63 ml. of acetic acid and 8.5 ml. of sulfuric acid was stirred at 8-12C. While the mixture was cooled and stirred, a solution of 15 grams oE sodium nitrite in 42 ml. of water was added dropwise over a period of about l hour. Stirring was continued for an additional 30 minutes. The mixture then was poured into a large volume of ice water. The resulting crude product was collected by filtration, thoroughly washed with water, and air dried while on the filter. The resulting crude nitroso compound then was added in portions to a stirred solution of 20 ml.
of 70 percent nitric acid and 60 ml. of water maintained a~
40-50C. Heating and stirring were continued until the evolution of brown fumes became negligible. The mixture then was poured into ice water, and the crude product was collected. The crude product then was recrystallized from ethanol-water to obtain a irst and a second crop. A total of 25.4 grams (70 percent) of 2-fluoro-4-nitro~5-methyl-phenol was obtained; m.p. 110-111.5C.
A mixture of 25 grams (0.15 mole) of the fluoro-nitrophenol, 22 grams of potassium carbonate, 15.4 ml. of dimethyl sulfate, and 550 ml. of ethanol was refluxed over-night. Analysis of the reaction mixture indicated that no alkylation had taken place. The mixture then was diluted with 300 ml. of N,N-dimethylformamide and about 50 ml. of water. Two equivalents of methyl iodide then were added.
The mixture was heated at 100C. overnight. The mixture then was cooled and added to a large volume of ice water.
The product separated, was collected by filtration, and dried. The collected product was recrystalli2ed from methanol-water to obtain 22.2 grams of 2-nitro-4-fluoro-5-methoxytoluene, m.p. 95-95.5C.
A mixture of 10 grams (0.054 mole) of the fluoro-nitrotoluene, 7.7 grams (0.065 mole) of N,N-dimethylformamide dimethylacetal, and 1.0 grams of triethylenediamine in 75 ml. of N,N-dimethylormamide was heated at 125C. under a gentle nitrogen sweep overnight. The solvent then was removed in vacuo with gentle application of heat. The ~ X-3964A -23 ':' . ~

~L~72~37 resulting residue was taken up in methanol and filtered to give a deep red-green iridescent product, m.p. 116-117C.
A total of 8.35 grams (64 percent) oE N,N-dlmethyl-2-(2'-nitro-4'-fluoro-5'-methoxyphenyl)ethyleneamine was obtained.
The ethyleneamine was hydrogenated in benzene over -~
Raney nickel. The resulting reaction mixture was washed with 500 ml. of water containing 4 ml. of phosphoric acid.
The resulting aqueous phase then was extracted with methylene chloride, and all the organic portions were combined. The combined organic solutions then were washed with aqueous sodium chloride solution and dried over sodium sulfate. The solvent then was removed in vacuo, and the resulting crude product was sublimed from a fused state at 0.2 mm. pressure.
The resulting sublimate was recrystallized from methanol-water to obtain a first and second crop totalling 3.02 grams (54 percent) of 5-methoxy-6-fluoroindole, m.p. 73-74C.
To a mixture o 2.8 ml. of 60 percent acetic acid -~
and 0.96 grams of diethylamine maintained at about 5C. was , .................... .
added 1.0 ml. of formalin. The resulting solution was added to a mixture of 2.0 grams (12.1 mmole) of the fluoroindole in 4 ml. of absolute ethanol. The solution was allowed to ; warm to room temperature and was stirred for about one hour.
The solution then was poured into 40 ml. of lN sodium hydroxide. The resulting mixture was extracted several times with ether. The ether extracts were combined and washed with aqueous sodium chloride solution, dried over sodium sulfate, and evaporated. The resulting residue was added to a solution of 40 ml. of methanol, 2 ml. of N,N-; dimethylformamide, 2 ml. of water, and 20 66 grams of sodium ~-~ X-3g64A -24-'`` .

cyanide. To tha resulting mixture then were added dropwise 4.2 ml. (9.6 grams; 0.068 mole) of methyl iodide over a period of about one hour. The resulting mixture was main-tained for about another hour. The mixture then was poured into ice water, and the aqueous mixture was extracted with methylene chloride. The extract was dried over sodium sulfate, and the solvent was removed ln vacuo. The residual product then was washed with a cold mixture of ether and petroleum ether. The product was recrystallized from benzene-hexane to obtain l.ll grams (45 percent) of 3-eyanomethyl-5-methoxy-6~fluoroindole, m.p. 97-98C.
A solution of l.9 grams (0.05 mole) of lithium aluminum hydride in 50 ml. of tetrahydrofuran was prepared and stirred under nitrogen. A solution of 1.3 ml. (2~45 grams; 0.025 mole) of lO0 percent sulfuric acid in 10 ml. of tetrahydrofuran was prepared and then was added to the lithium aluminum hydride solution~ The resulting mixture contained lithium sulfate as a suspension. A solution of l.0 grams (4.9 mmole) of the cyanomethylindole in lO ml. of tetrahydrofuran then was added to the mixture over a period of about 15 minutes. Stirring was continued for an addi-tional one hour. The reaction mixture then was poured into ice followed by 20 percent sodium hydroxide solution. The resulting mixture was extracted with severaL portions of chloroform. The extracts were washed with sodium chloride solution, dried over sodium sulfate, and the solvent was removed ln vacuo. The resulting residual oil crystallized ;~; upon addition of ether. The tan product was washed three times with small amounts of a 1:1 mixture of ether and ''' , ,''' ~LO~ 7 petroleum ether. Upon drying, 0.83 grams (81 percent) of 5-methoxy-6-fluorotryptamine was obtained. m.p. 114~117C.
Recrystallized from benzene-hexane, m.p. 120-121C.
A mixture of 0.75 grams (3.6 mmole) of the trypt-amine, 2.0 ml. of pyridine, and 8.0 ml. of benzene was pre-pared. Acetic anhydride ~1.0 ml.) was slowly added. The mixture was stirred at room temperature for four hours, and the solvents then were removed in vacuo with moderate heating. The resulting crystalline residue was dissolved in ; 10 a 1:1 mixture of warm ethyl acetate and chloroform. The solution was washed with water, then with sodium chloride solution, and then dried over sodium sulfate. The solvents were removed ln vacuo. The crystalline residue was boiled in ben7ene for a few minutes. The mixture was allowed to stand at room temperature for several hours, and the re-sulting product was collected by filtration and dried to obtain 0.81 grams (90 percent) of N-[2-(5-methoxy-6-fluoro-indol-3-yl)ethyl]acetamide, m.p. 158-159C.
Example 5 .
N-[2-(6-Chloro-5-methoxy-2-methylindol-3-yl)ethyl]acetamide To a solution of 20 g. (0.078 mole) of N,N-di-methyl-2-(2'-nitro-4'--chloro-5'-methoxyphenyl)ethyleneamine and 19.8 ml. (19.4 g., 0.25 mole) of pyridine in 200 ml. of methylene chloride was added dropwise a solution of 11 ml.
(12.2 g., 0.156 mole) of acetyl chloride in 200 ml. of methylene chloride. The addition was carried out over a period of about three hours. The mixture was stirred over-night and then was poured into a large volume of cold NaHCQ3 ; solution. The aqueous phase was extracted with fresh ~`

methylene chloride. The combined organic solutions were washed with water and dried over sodium sulfate. Removal of the solvent ln vacuo gave a residue which was dissolved in 450 ml. of dioxane. To the resulting solution were added 150 ml. of lM HCl solution. After stirring overnight at room temperature, the solution was refluxed for thre~ days.
After cooling, 80 ml. of lM NaOH were added, and the bulk of the dioxane was removed under reduced pressure. The product was then extracted into chloroform. The extract was evaporatedl and the residue was chromatographed over 200 g.
of florosil, eluting with benzene. Crystallization from benzene-hexane gave 6.49 g. (34% yield) of 4-chloro-5-methoxy-2-nitrophenylacetone, m.p. 114~115C.
Using 2 g. of Raney nickel, 6.49 g. (0.026 mole) of the arylacetone in 90 ml. of benzene were hydrogenated under 50 psi of hydrogen for 1 hour. The exothermic re duction caused the temperature to rise to 40C. After removal of the benzene, the residue was crystallized from methanol-water affording 1.5 g. of 6-chloro-5-methoxy-2-methylindole, m.p. 115-116C. Evapoxation of the mother liquor followed by sublimation and recrystallization from methanol-water provided another 0~62 g. of product, m.p.
114-115C. Total yield: 2.12 g., 41%.
A mixture oE 3.6 ml. (3.42 g. 0.047 mole) of DMF
and 1.04 ml. (1.74 g., 0.0114 mole) of phosphorus oxychloride was prepared at 10-20C. After 15 minutes, 2.05 g. (0.0105 mole) of the indole in 1 ml. of DMF was added, and the ~; temperature was raised to 35C. After one hour the mixture was poured onto crushed ice. This mixture was treated _ , . .

gradually with 2 g. of NaOH in 10 ml. of water~ maintainingan acidic pH through the first three-fourths of the addition.
Following acldition of the base, the mixture was boiled for one hour~ Aft~r the mixture was cooled and allowed to stand -overnight, the product was collected. Boiling the product in methanol afforded 2.13 g. (91% yield) of pure 6-chloro-5-methoxy~2-methylindole-3-carboxaldehyde, m.p~ 256 dec.
A mixture of 0.5 g. (0.002 mole) of the indole-carboxaldehyde, 40 ml. of nitromethane, 10 drops of acetic acid, and 0.4 g. of ammonium acetate was re1uxed overnight.
Another 0.4 g. of ammonium acetate was added, and the mixture was refluxed for an additional day. The ni~ro-methane was removed ln vacuo, and the xesidue was washed with water. Recrystalli2ation from ethanol gave 0.35 g.
(59% yield~ of pure 1-(6'-chloro~5'-methoxy-2' methylindol-3'-yl)-2-nitroethene, m.p. 238dec.
A solution of 1.47 g. (0.039 mole) of lithium aluminum hydride in 90 ml. of THF was stirred under nitrogen.
A solution of 1.02 mlu of sulfuric acid (100%) in 15 ml. of THF was added to the mixture followed by addition over a one hour period of a solution of 0.35 g. (0.0013 mole) of the nitrovinylindole in 15 ml. of THF. The mixture was stirred overnight, and the excess hydride then was destroyed by addition of ice chips. The mixture then was poured into a 20~ NaOH solution, and the total was extracted with several portions of chloroform. After drying over sodium sulfate, the solvent was removed rom the extracts, and the residue - was recrystallized from benzene-hexane. The yield of 6-chloro-5-methoxy-2-methyltryptamine, m.p. 152 153; was 3~ 0.50 g. (79%).

-A solution of 0.11 g. of the tryptamine in 5 ml.
of benzene and 0.37 ml. of pyridine was stirred in an ice bath. To the stirred mixture was added 0.05 ml of acetic anhydride. After stirring for one hour at room temperature, the mixture was poured into ice water and extracted with benzene. The benzene extract was dried over sodium sulfate and evaporated ln vacuo. The residue was chromatographed over 10 g. of silica gel eluting with ethyl acetate. The pure N-~2-(6-chloro-5-methoxy-2-methylindol-3-yl)ethyl]-acetamide, m.p. 119-121; weighing 0.11 g. (85~ yield) was recovered.
Example 6 N-[2-(1-Acetyl-5-methoxy-6-chloroindol-3-yl)ethyl]-acetamide.
To 30 ml. of N,N-dimethylformamide were added 210.7 mg. (0.79 mmole) of N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]acetamide (prepared as in Example 1) followed by 20.8 mg. of sodium hydride. The resulting mixture was stirred at room temperature for about one hour, and 68.2 mg.
(0.06 ml.) of acetyl chloride were added. The mixture wàs stirred for an additional hour and then was poured into ice ., .
water containing a small amount of acetic acid. The resulting mixture was extracted with chloroform, and the extract was washed twice with saturated aqueous sodium `~ chloride solution. The chloroform extract was dried over sodium sulfate and was concentrated in a rotary evaporator.

The residue was recrystallized from benzene-ether and was vacuum-dried to obtain 108 mg. (40.8~) of the title com-pound, m.p. 178-181C. ``~

: .

~ ":

``` 1IDf720~7 Analysis, Calc'd for C15H17N~O3Cl: C, 58.35; H, 5.55;
N, 9.07.
Found : C, 58.02*; H, 5.82*;
N, 9.07.*
*Result is an average of two analyses.
IR (KBr) 1646 (C=O~, 1703 cm 1 (C=O).
UV ~max ~MeOH) 256 (~ 17,200), 274 sh nm (~ 10,300).
NMR ~DMSO-d6) ~ 1.81 (g, 3H, amide Ac); 2.29 ~t, J--7 Hz., 2H, a-CH2); 2.58 (s, 3H, 1-Ac); 3.37 (q, J-7 Hz, 2H, ~-CH2); 3.90 (s, 3H, OCH3); 7.33 (s, lH, 4-H); 7.67 (s, lH, 2-H); 7.99 (broad t, lH, N-H); and 8.31 (s, lH, 7-H)~ `
The following Table is provided to show ovulation inhibitory activity of the compounds of formula I. Adult female rats with regular estrus cycles of four days each are employed. The estrus cycle consists of two days of diestrus followed by a day of proestrus and then a day of estrus. On the afternoon of proestrus, luteiniæing hormone (LH) is ; released into the blood by the pituitary gland. The LH
~ travels to the ovary where it induces ovulation, resulting `~20 in the presence of eggs in the oviduct on the day of estrus.
The test compound is administered orally at noon on the day of proestrus. The rat is sacrificed on the fol-`lowing day ~estrus), and the oviduct is removed and examined imicroscopically for the presence of ova. rrhe absence of ova -~indicates that the compound is active in blocking ovulation.
~...

`:;.
:
~' :

. , ....

Table Inhibiti n of Ovulation H3CQ~ --o--CH2-CHz-NH C R
~I~ ,D\ /~

: Inhibition R Rl XMin. Eff. Dose, mg.
H CH3 Ha 8 H CH3 Cl H C2H5 Cl H C3H7 Cl CH3 CH3 Cl 1 ~.

:.
'`:

.", ' :'';' .

. ' , . :
.,', ,~
;:
:' .;
. '~

:
i `~ X-3964A -31-

Claims (14)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A process for preparing 5-methoxy-6-halo-tryptamine compounds of the formula I

in which R is hydrogen, C1-C4 alkyl, phenyl, or phenyl substituted with halo, C1-C4 alkyl, or C1-C4 alkoxy;
R1 is hydrogen or C1-C4 alkyl;
R2 is hydrogen or R3, and R3 is haloacetyl, C1-C5 alkanoyl, benzoyl, or benzoyl substituted with halo or methyl; and X is halogen; which comprises reacting a 5-methoxy-6-halotryptamine compound of the formula II

wherein R and X are as defined above, with an active derivative of a carboxylic acid of the formula III
wherein R1 is as defined above; and if desired reacting the compound so obtained wherein R2 is hydrogen with an acylating agent of the formula R3-C1 IIIa wherein R3 is as defined above, in the presence of a strong base to provide the corresponding l-acyl compound.
2. 5-Methoxy-6-halotryptamine compounds of formula I wherein R, R1, R2, R3 and X are as defined in Claim 1, when prepared by the process of Claim 1 or by an obvious chemical equivalent thereof.
3. A process for preparing N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]acetamide which comprises reacting 5-methoxy-6-chlorotryptamine with acetic anhydride.
4. N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]-acetamide when prepared by the process of Claim 3 or by an obvious chemical equivalent thereof.
5. A process for preparing N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]propionamide which comprises reacting 5-methoxy-6-chlorotryptamine with propionic anhydride.
6. N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]-propionamide when prepared by the process of Claim 5 or by an obvious chemical equivalent thereof.
7. A process for preparing N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]butryamide which comprises reacting 5-methoxy-6-chlorotryptamine with butyryl chloride.
8. N-[2-(5-methoxy-6-chloroindol-3-yl)ethyl]-butyramide when prepared by the process of Claim 7 or by an obvious chemical equivalent thereof.
9. A process for preparing N-[2-(5-methoxy-6-fluoroindol-3-yl)ethyl]acetamide which comprises reacting 5-methoxy-6-fluorotryptamine with acetic anhydride.
10. N-[2-(5-methoxy-6-fluoroindol-3-yl)ethyl]-acetamide when prepared by the process of Claim 9 or by an obvious chemical equivalent thereof.
11. A process for preparing N-[2-(5-methoxy-6-chloro-2-methylindol-3 yl)ethyl]acetamide which comprises reacting 5-methoxy-6-chloro-2-methyltryptamine with acetic anhydride.
12. N-[2-(5-methoxy-6-chloro-2-methylindol-3-yl)ethyl]acetamide when prepared by the process of Claim 11 or by an obvious chemical equivalent thereof.
13. A process for preparing N-[2-(1-acetyl-5-methoxy-6-chloroindol-3-yl)ethyl]acetamide which comprises reacting 5-methoxy-6-chlorotyptamine with acetic anhydride;
followed by reaction with acetyl chloride in the presence of sodium hydride.
14. N-[2-(1-acetyl-5-methoxy-6-chloroindol-3-yl)ethyl]acetamide when prepared by the process of Claim 13 or by an obvious chemical equivalent thereof.
CA263,700A 1975-10-29 1976-10-19 Amides as ovulation inhibitors Expired CA1072087A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62689075A 1975-10-29 1975-10-29
US05/720,311 US4087444A (en) 1976-09-08 1976-09-08 Amides as ovulation inhibitors

Publications (1)

Publication Number Publication Date
CA1072087A true CA1072087A (en) 1980-02-19

Family

ID=27090276

Family Applications (1)

Application Number Title Priority Date Filing Date
CA263,700A Expired CA1072087A (en) 1975-10-29 1976-10-19 Amides as ovulation inhibitors

Country Status (9)

Country Link
JP (1) JPS6025421B2 (en)
CA (1) CA1072087A (en)
CH (1) CH602638A5 (en)
DE (1) DE2645865A1 (en)
FR (1) FR2329274A1 (en)
GB (1) GB1562825A (en)
IE (1) IE43725B1 (en)
IL (1) IL50536A (en)
NL (1) NL7611971A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047936C (en) * 1987-02-02 2000-01-05 伊莱利利公司 Method for producing pharmaceutical composite containing alkylmelatonins
ZA88498B (en) * 1987-02-02 1989-10-25 Lilly Co Eli Alkylmelatonins
US5763471A (en) * 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
AU1197299A (en) * 1997-10-28 1999-05-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2001520996A (en) * 1997-10-28 2001-11-06 メルク エンド カムパニー インコーポレーテッド Gonadotropin-releasing hormone antagonist
US8053462B2 (en) 2004-03-08 2011-11-08 Masanori Somei Indole derivative and application thereof
JP3964417B2 (en) 2004-09-27 2007-08-22 国立大学法人金沢大学 Α2 receptor blocker and vasodilator containing indole derivative as active ingredient
CA2952857A1 (en) * 2014-06-19 2015-12-23 Merial, Inc. Parasiticidal compositions comprising indole derivatives, methods and uses thereof

Also Published As

Publication number Publication date
JPS5257169A (en) 1977-05-11
FR2329274A1 (en) 1977-05-27
CH602638A5 (en) 1978-07-31
IL50536A (en) 1980-03-31
GB1562825A (en) 1980-03-19
IL50536A0 (en) 1976-11-30
DE2645865C2 (en) 1988-07-07
DE2645865A1 (en) 1977-05-12
IE43725B1 (en) 1981-05-06
FR2329274B1 (en) 1978-12-22
NL7611971A (en) 1977-05-03
JPS6025421B2 (en) 1985-06-18
IE43725L (en) 1977-04-29

Similar Documents

Publication Publication Date Title
US4087444A (en) Amides as ovulation inhibitors
US4587246A (en) 1,3,4-thiadiazin-2-ones
US4166907A (en) 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
SI9210305A (en) Indole derivatives, processes for their preparation and medicaments containing them
CA1072087A (en) Amides as ovulation inhibitors
US5110831A (en) Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
US4997845A (en) β-alkylmelatonins as ovulation inhibitors
US4656192A (en) Tropolone derivatives, processes for the preparation thereof and the use thereof as anti-tumor agents
GB1588242A (en) N-(tetrazol-5-yl)-salicylamide derivatives
US4442115A (en) 2'Hydroxy tetrazole-5-carboxanilides and anti-allergic use thereof
US3564009A (en) Process for producing 1-acylindole derivatives
US4139538A (en) Oxazolidinones as therapeutic agents
CA1088533A (en) 3,3-dichloro-2-azetidinone derivatives having antiinflammatory activity
KR960004859B1 (en) Ñô-alkylmelatonins as ovulation inhibitors
NO127054B (en)
FR2580281A1 (en) NITROFURAN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CA1129413A (en) Tetrahydrothiopyrano ¬2,3-b| indole derivatives
SU784763A3 (en) Method of preparing 6-methoxy-2-acetylnaphthyloxime derivatives of their hydrochlorides
US4086361A (en) Aminoethyl oximes having anti-depressive activity
US4179442A (en) 4-(Alpha-hydroxy-isopropyl)-5-phenyl-oxazolidin-2-one
US3978057A (en) Substituted amino-hydrazinopyridazines
US3978044A (en) Indazole derivatives, processes for making the same and pharmaceutical compositions
US4065617A (en) 2-(2,2,2,-Trifluoroethyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridines
US4065571A (en) Antiviral 5-(substituted benzal) hydantoins
GB2126230A (en) Substituted 1-pyridyloxy-3- indolylakylamino-2-propanols, preparation, and use thereof

Legal Events

Date Code Title Description
MKEX Expiry